Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses
Currently, there is a huge demand to develop chemoimmunotherapy with reduced systemic
toxicity and potent efficacy to combat late-stage cancers with spreading metastases. Here …
toxicity and potent efficacy to combat late-stage cancers with spreading metastases. Here …
Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses
Cancer immunotherapy by educating or stimulating patients' own immune systems to attack
cancer cells has demonstrated promising therapeutic responses in the clinic. However …
cancer cells has demonstrated promising therapeutic responses in the clinic. However …
Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
Immune checkpoint blockers (ICBs) have shown great promise at harnessing immune
system to combat cancer. However, only a fraction of patients can directly benefit from the …
system to combat cancer. However, only a fraction of patients can directly benefit from the …
[HTML][HTML] Sensitizing protective tumor microenvironments to antibody-mediated therapy
CP Pallasch, I Leskov, CJ Braun, D Vorholt, A Drake… - Cell, 2014 - cell.com
Therapy-resistant microenvironments represent a major barrier toward effective elimination
of disseminated malignancies. Here, we show that select microenvironments can underlie …
of disseminated malignancies. Here, we show that select microenvironments can underlie …
Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy
Q Shang, Y Dong, Y Su, F Leslie, M Sun… - Advanced Drug Delivery …, 2022 - Elsevier
Cancer immunotherapy, which reprograms a patient's own immune system to eradicate
cancer cells, has been demonstrated as a promising therapeutic strategy clinically. Immune …
cancer cells, has been demonstrated as a promising therapeutic strategy clinically. Immune …
Immunogenic cell death amplified by co-localized adjuvant delivery for cancer immunotherapy
Despite their potential, conventional whole-cell cancer vaccines prepared by freeze–
thawing or irradiation have shown limited therapeutic efficacy in clinical trials. Recent …
thawing or irradiation have shown limited therapeutic efficacy in clinical trials. Recent …
[HTML][HTML] Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors
Poorly immunogenic tumors, including triple negative breast cancers (TNBCs), remain
resistant to current immunotherapies, due in part to the difficulty of reprogramming the highly …
resistant to current immunotherapies, due in part to the difficulty of reprogramming the highly …
[HTML][HTML] Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence
C Song, H Phuengkham, YS Kim, VV Dinh, I Lee… - Nature …, 2019 - nature.com
The low response rate of current cancer immunotherapy suggests the presence of few
antigen-specific T cells and a high number of immunosuppressive factors in tumor …
antigen-specific T cells and a high number of immunosuppressive factors in tumor …
[HTML][HTML] Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity
Anti-tumour inflammatory cytokines are highly toxic when administered systemically. Here, in
multiple syngeneic mouse models, we show that the intratumoural injection of recombinantly …
multiple syngeneic mouse models, we show that the intratumoural injection of recombinantly …
In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
Patients with low-immunogenic tumors respond poorly to immune checkpoint blockade (ICB)
targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway …
targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway …